Proteome Sciences Wins Two More Major GCLP Contracts Worth Over $1.5m

Proteome Sciences ( (GB:PRM) ) has shared an announcement.

Proteome Sciences has secured two additional substantial GCLP contracts worth over $1.5 million, following an earlier announcement in December 2025, with trial samples scheduled to be shipped in late Q1 and most of the work to be completed during 2026. Management highlighted sustained strong demand from major biopharma clients in both the US and Europe, indicating that these new wins, combined with previously announced contracts, provide a robust order book that underpins the company’s revenue visibility and operational outlook through 2026.

The most recent analyst rating on (GB:PRM) stock is a Hold with a £2.50 price target. To see the full list of analyst forecasts on Proteome Sciences stock, see the GB:PRM Stock Forecast page.

Spark’s Take on GB:PRM Stock

According to Spark, TipRanks’ AI Analyst, GB:PRM is a Neutral.

Proteome Sciences’ overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and negative profitability. While the technical analysis shows some positive momentum, the valuation remains unattractive due to ongoing losses. The recent corporate event is a positive development, potentially improving future prospects.

To see Spark’s full report on GB:PRM stock, click here.

More about Proteome Sciences

Proteome Sciences plc is a UK-listed life sciences company specialising in proteomics, providing Good Clinical Laboratory Practice (GCLP) analytical services to major biopharmaceutical clients in the US and Europe. Its work supports clinical trials by analysing trial samples, positioning the company within the growing market for outsourced biomarker and proteomic testing services.

Average Trading Volume: 268,476

Technical Sentiment Signal: Hold

Current Market Cap: £8.41M

Find detailed analytics on PRM stock on TipRanks’ Stock Analysis page.